February 5, 2026
FOCUS On Kinase Inhibitors. The FDA recently approved its 100th kinase inhibitor, marking a major milestone in precision medicine since its first kinase inhibitor approval (Imatinib) […]
January 20, 2026
FOCUS on Alzheimer’s disease. A recent paper by AA Pieper and colleagues demonstrated that pharmacologic restoration of NAD+ homeostasis with P7C3-A20 reverses cognitive deficits and neuropathology […]
December 30, 2025
FOCUS on Drug Failures. On December 22nd AstraZeneca reported on the LATIFY Phase III trial of ATR inhibitor ceralasertib (AZD6738) in combination with Imfinzi (Durvalumab), which […]
December 23, 2025
FOCUS on Clinical Trials. Takeda has announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib […]
December 19, 2025
FOCUS on Drug Approvals. On December 17th the FDA granted regular approval to PARP inhibitor drug Rubraca (Rucaparib, pharmaand GmbH), for treatment of adults with a […]
December 16, 2025
FOCUS on Drug Failures. Yesterday Sanofi provided an update on tolebrutinib (SAR442168, a Bruton tyrosine kinase inhibitor), in primary progressive multiple sclerosis. Results from the PERSEUS […]
December 5, 2025
FOCUS on Drug Approvals. The FDA has approved the first cancer drug based on discoveries from the Broad Institute of MIT and Harvard. Sevabertinib (BAY-2927088) was […]
November 26, 2025
FOCUS Biomolecules is a Philadelphia-based company, and we are celebrating the American Society for Cell Biology annual meeting in Philly! Visit us at ASCB booth #1424 […]
November 24, 2025
FOCUS on New Drug Approvals. On November 13th the FDA announced approval of Ziftomenib (Komzifti, Kura Oncology), a menin inhibitor, for the treatment of adults with […]